Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Hepatorenal syndrome-acute kidney injury (HRS-AKI), a potentially reversible renal failure,
is a serious, rapidly progressing, often fatal, complication of decompensated cirrhosis.
Terlipressin is a synthetic vasopressin analogue that acts as a systemic vasoconstrictor via
the vascular vasopressin V1 receptors. In HRS-AKI patients the strong V1 receptor-mediated
vasoconstrictor activity of terlipressin, particularly in the splanchnic area, increases
effective intravascular volume and mean arterial pressure (MAP), ameliorates
renin-angiotensin-aldosterone system and sympathetic nervous system hyperactivity, and
improves renal blood flow. The INFUSE trial will evaluate the use of continuous terlipressin
infusion in patients on the liver transplant waiting list with HRS-AKI.